Journal of Cardiovascular Disease Research

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

A REVIEW ON HYPERTROPHIC CARDIOMYOPATHY

Uppuluri Spandana*[1], Pallepati Lakshmaiah[2], Sabbarapu Sharon Namitha[1], Nallagorala Pramodh[1] Venkata Sai[1], Guntaka Kavyasri[1], Vatturi Sai Sudeep[1]

[1] Department of Pharmaceutical Chemistry and Phyto Chemistry,[2] Department of Pharmacology and Pharmacy Practice Nirmala College of Pharmacy, Atmakur, Mangalagiri, Guntur.

Corresponding mail Id: spuppuluri@gmail.com

ABSTRACT:

Hypertrophic Cardiomyopathy is hereditary heart disease with clinical and pathological manifestations. It affects the left ventricle and is mostly caused by increased ventricular thickness (hypertrophy) with no clear reason. This causes left ventricular outflow blockage, diastolic dysfunction, myocardial ischemia, and mitral regurgitation. It is also a leading cause of sudden cardiac death, particularly in teenagers and young adults.

Hypertrophic Cardiomyopathy (HCM) is caused by mutations in one of the multiple genes; the most often affected genes are MYH7, MYBPC3, TNNT2, and TNNI3. Proteins generated by genes serve a crucial part in the contraction of cardiac muscle units known as "sarcomeres." MYH7 and MYBPC3 gene mutations account for about 80% of HCM. Many people who have the HCM disease gene do not have a clinically evident illness. Shortness of breath, and decreased blood filling of the ventricles, angina, palpitations, lightheadedness, weakness, fainting, and sudden cardiac death are all signs of HCM. Surgery, an implanted device, or medicine to reduce or control the heart rate may be used as treatment. However, it is unclear how mutations in sarcomere-related genes produce hypertrophy of heart muscle or the symptoms of familial HCM.

Keywords: Hypertrophy, cardiomyopathy, gene mutation, sarcomere, palpitations, angina.

Introduction:

Hypertrophic Cardiomyopathy is now recognized as a worldwide illness, with instances documented on all continents, affecting persons of all genders and racial and cultural backgrounds. Despite its many manifestations, the illness is characterized by comparable genotypic defects and the unifying phenotypic expression of left ventricular hypertrophy (LVH). Muscle cells in the typical heart are regular and patterned. The cells of the heart muscle become irregular and disorganized in hypertrophic cardiomyopathy. The region most often affected is the muscle around the left ventricle. The thickening may partially restrict blood flow from your left ventricle into your aorta.

Heart:

The heart is a muscular organ situated between the lungs and somewhat to the left of the breastbone. The heart is roughly the size of a fist and pumps blood to all areas of the body via a network of arteries and veins known as the cardiovascular system or circulatory system.

The heart is a vital organ that the body needs to conduct vital activities. The following are the primary functions of the heart:

- Blood enters the right atrium from the veins and is pumped to the right ventricle. (Getting deoxygenated blood)
- From the right atrium, the blood is received by the right ventricle and it pumps to the lungs (loaded with oxygen)
- From the lungs, the oxygenated blood is received by the left atrium and it pumps to the left ventricle.

- The left ventricle (strongest chamber of the heart)
  pumps oxygenated blood to other parts of the body. (pumping oxygenated blood)

It carries metabolic waste products from the body to the lungs for oxygenation and it also pumps hormones and other vital substances to other parts of the body. A protective sac filled with fluid surrounding the heart is called the pericardium.[(5)(6)(7)]

Four chambers of the heart are:

- Two receiving chambers (upper atria)
- Two evacuating chambers (lower ventricle)



Anatomy Of Heart

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

The Strongest Chamber: The *Left Ventricle* is one of four chambers responsible for delivering oxygenated blood to the aorta and the rest of the body. It is longer and conical in shape, forming the heart's apex. It is the thickest of the four chambers and is positioned below the left atrium, divided by the mitral valve.

Thickest at base = 10-15mm (avg)

- For men = 13.6mm
- For women = 11.2mm

Thinnest at apex = 1-2mm



It is the most active chamber of the heart. It delivers blood throughout the body. It has trabeculae carneae and chordae tendineae that anchor the bicuspid cusps.

the valve to the papillary muscles It has a strong resistance to blood flow and pumps the blood at a greater pressure. It has to work harder than the right ventricle to keep the blood flowing at the same rate. Based on the longitudinal alignment of the myocardial strands, the left ventricle is divided into three levels :

- subepicardial (outer) – approx. 25% of thickness
- middle - approx. 53 – 59% of thickness
- subendocardial (inner) - <20% of thickness (thin layer) [8] [9] [10]

Cardiomyopathy: It is defined as "an illness characterized by morphologically and functionally aberrant myocardium in the absence of any other disease that, by itself, is sufficient to induce the observed phenotype" [11].

A cardiac condition characterized by anatomical and functional abnormalities in the heart muscle. In the absence of coronary artery disease, hypertension, valvular disease, or congenital heart disease, the detected myocardial abnormality is sufficient to induce the reported myocardial abnormality [12].

With a population frequency of 1 in 500, hypertrophic cardiomyopathy (HCM) is the most prevalent hereditary cardiovascular illness. [13][14]

According to a recent study, the frequency is most likely 1 in 200[15]. HCM is the main cause of sudden death in young athletes and a common cause of sudden death in teenagers [16][17]. About half of all HCM instances are inherited, and this variety is known as familial HCM (FHCM) [18]. HCM etiology is largely linked to cardiac sarcomere protein mutations, with over 1,400 HCM mutations identified in at least 20 genes [19][20]. FHCM is sometimes referred to as a sarcomere disease. Furthermore, FHCM is morphologically varied, significantly divergent within families, and has significant genetic diversity. [21]

Asymmetric Septal Hypertrophy:



Hypertrophic cardiomyopathy is a condition defined by abnormally thickened (hypertrophied) heart muscle, making it difficult for the heart to pump blood. It can be inherited and is caused by faulty genes that allow the heart to develop abnormally, leading to chest discomfort, shortness of breath, diastolic dysfunction, sudden cardiac death, and rhythmic heart abnormalities. [22,23,24]



The HCM is an autosomal dominant trait caused by a single mutation. HCM is caused by gene mutations in multiple genes that encode sarcomere-associated proteins, primarily nonsense MYBPC3 and missense MYH7 variations. In recent years, there has been a rise in the number of genes identified as disease-causing. The disease has complicated symptomatology and has the potential to be catastrophic for sufferers and their families. In preadolescent and adolescent children, HCM is the primary cause of sudden cardiac mortality. The disease is distinguished

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

by inappropriate, frequently asymmetrical cardiac hypertrophy that develops in the absence of an apparent initiating hypertrophy stimulus. Hypertrophy can develop in any area of the left ventricle, although it most commonly affects the IVS, resulting in a blockage of flow through the LVOT. HCM prevalence: 0.05-0.25 percent of the population [25,26,27,28]

• this prevalence is greater than previously assumed, implying a significant number of afflicted yet undiagnosed persons. The majority of instances have been recorded from the United States, Canada, Western Europe, Israel, and Asia.

Genetic testing broadens the HCM illness range and allows for the identification of HCM phenocopies with diverse natural histories and therapeutic choices, but it is not a viable method for predicting prognosis. The interaction of a diverse illness like HCM with the huge genetic diversity of the human genome and the high frequency of new mutations has produced unexpected challenges in translating sophisticated science (and language) into the clinical arena. [29,30,31]

History :

Teare discovered severe hypertrophy of the ventricular septum in a small group of young patients who died suddenly in 1958.[32,33,)]

Braunwald was the first to make a clinical diagnosis of HCM in the 1960s. There are numerous names for the condition. [34]

- Idiopathic hypertrophic subaortic stenosis (IHSS)
- Subaortic stenosis of the muscles
- Cardiomyopathy with hypertrophic obstructive hypertrophy (HOCM) [35,36,37]

In the early 1970s, echocardiography enabled noninvasive imaging of left ventricular hypertrophy (LVH) and accurate identification of family members with and without the HCM phenotype [38]. In 1989, by combining deoxyribonucleic acid (DNA)–based methods and traditional segregation linkage analysis with echocardiography, researchers were able to map HCM to a causal locus on chromosome 14. [39]. In 1990, sequence analysis of a candidate gene identified a pathogenic missense mutation in the beta-myosin heavy chain gene (MYH7Arg 403 Gln) to be responsible for HCM [40]

Genetics basis :

Over nine different sarcomere genes with over 1400 mutations are associated in the autosomal dominant inheritance with incomplete penetrance, however, 80 percent of patients have a mutation in either MYH7 or MYBPC3. The genetic basis of ventricular hypertrophy has no direct relationship with predictive risk categorization. Mutations in the number of sarcomeres result in increased calcium sensitivity, maximal force output, and ATPase activity. Mutation and hypertrophy cause abnormal energetics and poor relaxation.[41,42,43,44]

Morphology:

- Left ventricular hypertrophy
- Mitral valve apparatus
- Histopathology

Left ventricular hypertrophy: HCM is characterized by asymmetric LV hypertrophy in various patterns. The thickness of one or more portions of the LV wall is usually greater than in other locations. Extension into the right ventricle, as well as sharp transitions in thickness between adjacent sections or noncontiguous patterns of segmental hypertrophy. There is no single "classic" morphologic type of LVH, and almost all potential patterns of LVH, including normal LV wall thicknesses, have been observed. [45]

Mitral valve apparatus: Valvular size and shape changes can occur in a variety of ways and are a main morphologic anomaly in HCM. Elongation of both leaflets or segmental enlargement of only the anterior leaflet or the midportion of the posterior leaflet might cause the valve to be twice its normal size. [46]

Histopathology: Cardiac muscle cells have a larger transverse diameter and odd forms, and they frequently retain intercellular connections with multiple neighboring cells. At oblique and perpendicular angles, myocytes (and myofilaments) are grouped in a chaotic, disordered manner. Abnormal intramural coronary arteries with thicker walls (consisting of enlarged intimal and medial components) and constricted lumens are seen in 80 percent of patients, most commonly inside or near regions of replacement fibrosis, leading to microvascular ischemia and angina. [47]

There are two forms of HCM: an obstructive type (70 percent) and a non-obstructive type (HNCM; in all cases of HCM, testing should be conducted to detect outflow blockage at rest and/or on provocation, and therefore establish whether HOCM or HNCM is present. [48]

Etiology :

PRIMARY HCM- a hereditary illness with AD inheritance.



ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021



SECONDARY HCM- metabolic, mitochondrial, and syndromic illnesses such as Noonan and Leopard syndromes. Usually manifests itself in infancy (15 percent of infants with HCM). Develop concentric HCM, which is frequently accompanied by involvement of the right ventricle. Muscle biopsy, metabolic screening. [49]

Pathophysiology:

HCM Pathophysiology: HCM pathogenesis is comprised of four interconnected processes: left ventricular outflow restriction, diastolic dysfunction, myocardial ischemia, and mitral regurgitation.

LV obstruction restriction: Long-term LV outflow blockage in HCM is a key predictor of heart failure symptoms and mortality in HCM patients. Subaortic outflow obstruction is produced by mitral valve systolic anterior motion (SAM), in which the leaflets migrate toward the septum. Long-term LV outflow obstruction in HCM is a significant predictor of heart failure symptoms and death in HCM patients. Mitral valve systolic anterior motion (SAM), which causes the leaflets to move toward the septum, causes subaortic outflow blockage. Physiological Consequences of Obstruction:

- Elevated intraventricular pressures
- Prolongation of ventricular relaxation
- Increased myocardial wall stress Increased oxygen requirement
- Decrease in forwarding cardiac output

Diastolic Dysfunction

- ✓ a contributing factor in 80% of patients
- ✓ Impaired relaxation
- ✓ High systolic contraction load
- ✓ Ventricular contraction/relaxation not consistent
- ✓ Accounts for exertional dyspnea symptoms
- ✓ Increased filling pressures
- ✓ Increased pulmonary venous pressure

Myocardial Ischemia : It occurs often in the absence of atherosclerotic coronary artery disease. Postulated causes include abnormally tiny and partly destroyed intramural coronary arteries caused by hypertrophy. Inadequate capillary density for the degree of LV mass, resulting in increased myocardial oxygen demand and higher filling pressures, resulting in subendocardial ischemia.

Mitral Regurgitation (MR) : It is caused by the systolic anterior motion of the mitral valve. Variations in leaflet length (posterior/anterior leaflet length mismatch) – restrict the ability of the posterior leaflet to follow the anterior leaflet and coapt effectively, resulting in MR. The severity of MR is directly proportional to LV outflow obstruction. [50]

Non-pathogenic mutations:

Many amino acid changes in DNA sequence, on the other hand, do not cause illness and are considered as benign polymorphisms (i.e., variations not typically thought to be harmful), occurring in >0.5% to 1.0% of ethnic-specific normal control groups. Nonetheless, even after applying all pathogenicity criteria, the significance for producing disease connected to a large proportion of such discovered variations remains unknown. As a result, genetic test results classify these mutations as ambiguous (i.e., variations of unknown significance [VUS or VOUS]) with little clinical use for family screening[51][52][53]

Indeed, identifying pathogenic mutations from VUS or uncommon nonpathogenic variations has become increasingly difficult when interpreting testing findings in HCM, and has been dubbed the diagnostic strategy's "Achilles heel". This problem has grown especially difficult as technology has become more affordable, allowing for thorough DNA sequencing of the exome and even the entire genome. While providing scientific insights, this advancement also significantly enhances the identification of VUS, perhaps leading to even more uncertainty in test findings. [54][55][56]

Notably, there are presently no universally recognized criteria for interpreting VUS, with estimated rates ranging from 5% to 50%, primarily depending on the number of pathogenicity classes used to classify mutations and the number of genes in the testing panel. Laboratory commercial testing techniques vary greatly, with 3 to 7 descriptive pathogenicity classifications used to produce formal reports, raising the risk that various interpretations of pathogenicity may emerge from different laboratories for the same mutation. [57]

Indeed, it is not well recognized in the clinical cardiovascular community that molecular diagnosis and assignment of mutations to pathogenic status is frequently done on a probabilistic basis, rather than as a definite binary test result. Certainly, the original genotyping expectation barrier may have been set too high, considering the very few definite scenarios that arise in HCM, and the pathogenicity of sequence variations is sometimes difficult to prove with certainty. [58]

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

From 2013 to 2017, 387 HCM probands and their families had their clinical data gathered. All probands were subjected to targeted exome sequencing, and the chosen mutations were confirmed by Sanger sequencing in the probands, family relatives, and 300 healthy ethic matched volunteers. SwissPdbViewer 4.1 was used to build three-dimensional models, and genetic studies were done to evaluate sequence conservation and mutation frequency. Four of the five probands with double MYH7 mutations had compound heterozygous mutations, whereas one had monoallelic double mutations (A934V and E1387K). [(59)]

Variants of HCM:

Subaortic, septal, and ant. wall are the most prevalent locations.

• Asymmetric hypertrophy (septum and anterior wall): 70%
• 15% to 20% basal septal hypertrophy
• Concentric LVH: 8% to 10%
• Apical or lateral wall: 2% (25 percent in Japan/Asia): distinctive huge T-wave inversion laterally & spade-like left ventricular cavity: less harmful[(60,61)]

Hemodynamics:

In HCM, the left ventricle has a normal end-diastolic volume, a high-normal (65–70%) or increased (>70%) ejection fraction, and a decreased end-systolic volume. The hypertrophied septum is encroaching on the LVOT. There is systolic anterior motion (SAM) of the anterior leaflet of the mitral valve in the presence of hyperdynamic ejection, which abuts the hypertrophied interventricular system during systole, obstructing outflow. This is reflected in a systolic pressure gradient between the left ventricular cavity and the aorta that is present at rest in about one-third of individuals with HCM. The blockage is dynamic in nature, which is a distinguishing characteristic of HCM.[(62,63)]

The degree of the LVOT blockage is determined by ventricular volume, which is determined by the interplay of myocardial contractility, ventricular preload, and afterload. Increases in contractility, as well as decreases in preload and afterload, reduce ventricular volume and induce or worsen blockage; decreases in contractility and increases in preload and afterload have the opposite effect.[(64,65,66)] Thus, muscular activity, isoproterenol infusion, amyl nitrite inhalation, sublingual nitroglycerin, and the strain phase of the Valsalva maneuver can all cause LVOT blockage in HCM patients who do not have a resting gradient.[(67,68,69)]

Diastolic dysfunction is common in HCM. It is caused by increased interstitial fibrosis, as well as delayed relaxation and stiffening of the thicker ventricular wall. In individuals with HCM, left atrial volume, an indirect measure of left ventricular diastolic pressure, is frequently elevated and is a predictor of the development of atrial fibrillation and heart failure. Pulsed and tissue Doppler imaging, 3-dimensional speckle tracking echocardiography, and magnetic resonance imaging all show that regional systolic myocardial function is often compromised. Systolic function decreases, the left ventricular wall thins, the cavity enlarges, and heart failure with decreased ejection fraction occurs in around 5% of HCM patients, mainly older individuals with significant, persistent LVOT blockage and severe interstitial fibrosis. [(70,71,72,73,74)]



Symptoms:

Some persons with the disease may not exhibit any symptoms. They may discover they have the issue during a normal medical exam.

The initial sign of hypertrophic cardiomyopathy in many young people is abrupt collapse and death. This can be caused by extremely aberrant cardiac rhythms (arrhythmias). It might also be caused to a blockage that prevents blood from flowing from the heart to the rest of the body. [(75)]

Typical symptoms include:

- Chest ache
- Dizziness
- Fainting, particularly during activity
- Fatigue
- Lightheadedness, particularly during or after physical activity or exercise

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

- Feeling that your heart is beating quickly or erratically (palpitations)
- Shortness of breath during physical exercise or after lying down (or have been sleeping for a time) (76,77)

HCM is a chronic condition that can worsen with time. This can result in decreased function and quality of life, long-term problems, and an increase in financial and social load. To compensate for their condition, people with HCM frequently need to undertake lifestyle modifications, such as reducing their activities. (78)



As HCM develops, it might lead to additional health issues. HCM patients are more likely to develop atrial fibrillation, which can lead to blood clots, stroke, and other heart-related problems. HCM can potentially cause cardiac failure. It can also cause abrupt cardiac arrest, however, this is uncommon. (79)(80)

Prior history of cardiac arrest or ventricular fibrillation, spontaneous sustained ventricular tachycardia, abnormal exercise blood pressure, and non-sustained ventricular tachycardia, unexplained syncope, family history of premature sudden death, and LVW thickness greater than 15 mm to 30 mm on echocardiogram are all major risk factors for sudden death in people with HCM. A physical examination can also reveal the "spike and dome" pulse and the "triple ripple apical impulse." (81) (82)(83)

Diagnosis :

The doctor would most likely prescribe testing to rule out other diseases that might give similar symptoms to hypertrophic cardiomyopathy (HCM).



Echocardiogram: To diagnose hypertrophic cardiomyopathy, echocardiography is often utilized. This test utilizes sound waves (ultrasound) to determine if the muscle in your heart is unusually thick. It also indicates how successfully your heart's chambers and valves pump blood. Echocardiography is sometimes performed while you exercise, generally on a treadmill. This is referred to as an exercise stress test. Treadmill stress tests are frequently used to identify hypertrophic cardiomyopathy. (84)

Electrocardiogram(ECG or EKG): Sensors (electrodes) coupled to adhesive pads are put on your chest and, in certain cases, on your legs. They take electrical impulses from your heart and analyze them. An ECG can detect irregular cardiac rhythms as well as indications of heart thickening. In some situations, a portable ECG known as a Holter monitor is required. This gadget continually monitors your heart's activity for one to two days. (85)

MRI of the heart: A cardiac MRI creates pictures of your heart using strong magnets and radio waves. It provides your doctor with information about your heart muscle and demonstrates how your heart and heart valves function. This test is frequently combined with echocardiography. (86)

HCM is frequently diagnosed and treated by a cardiologist or pediatric cardiologist. You may also be referred to a cardiomyopathy center, where the medical staff is specially trained.

HCM is diagnosed based on your medical history, family history, physical exam, and the results of diagnostic tests.(87,88)

Treatment:

The objective of hypertrophic cardiomyopathy therapy is to alleviate symptoms and avoid sudden cardiac death in high-risk patients. precise therapy will be determined by the severity of your symptoms. a doctor will explore the best treatment option for your problem. (89)

The following medications may be used to treat hypertrophic cardiomyopathy and associated symptoms:

- Metoprolol (Lopressor, Toprol-XL), propranolol (Inderal, Innopran XL), and atenolol are examples of beta-blockers (Tenormin)
- Calcium channel blockers like verapamil (Verelan, Calan SR,) and diltiazem (Cardizem, Tiazac)
- Amiodarone (Pacerone) and disopyramide are both heart rhythm medications (Norpace)

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

- If you have atrial fibrillation, you should take blood thinners such as warfarin (Coumadin, Jantoven), dabigatran (Pradaxa), rivaroxaban (Xarelto), or apixaban (Eliquis) to avoid blood clots.

Cardiomyopathy or its symptoms can be treated with a variety of operations or treatments. They range from open-heart surgery to the implantation of a gadget that regulates your heartbeat. (90)

Myectomy of the septum: If medicines do not relieve your symptoms, open-heart surgery may be suggested. It entails removing a portion of the thicker, overgrown wall (septum) that separates the heart chambers. Septal myectomy improves blood flow out of the heart and decreases backflow through the mitral valve (mitral regurgitation). (91)

Depending on the location of the thickened heart muscle, the operation may be performed in a variety of ways. One form, known as apical myectomy, involves the removal of thickened cardiac muscle around the apex of the heart by surgeons. Sometimes the mitral valve is repaired at the same time as the aortic valve.

Ablation of the septum: Alcohol is used in this technique to eliminate the swollen heart muscle. The alcohol is injected into the artery providing blood to that region through a long, thin tube (catheter). Complications may include a disturbance of the heart's electrical system (heart block),.which necessitates the installation of a pacemaker. (92,93)



Cardioverter-defibrillator implant (ICD) : An implantable cardioverter-defibrillator (ICD) is a tiny device that continually monitors your heartbeat. It is inserted in your chest, similar to a pacemaker. In the event of potentially fatal arrhythmia, the ICD administers carefully calibrated electrical shocks to restore normal cardiac rhythm. ICD has been found to help avoid sudden cardiac death, which happens in a tiny percentage of hypertrophic cardiomyopathy patients. (94,95,96)

Research studies :

While current pharmacological or interventional treatments for HCM patients are often helpful in alleviating or avoiding symptoms, they do not address either the underlying genetic abnormality or the critical intermediate processes involved in the phenotype's development. As a result, they are ineffective in the prevention or promotion of heart hypertrophy and fibrosis regression. The understanding of HCM's molecular genetics and pathophysiology is spurring the creation and testing of a variety of pharmaceutical treatments. (97,98,99)

Preliminary research in animal models of HCM showed that angiotensin II receptor blockers, 3-hydroxy-3-methyglutaryl-coenzymeA (HMG-CoA) reductase inhibitors (statins), mineralocorticoid receptor blockers, and the antioxidant N-acetylcysteine. Despite the positive benefits of several of these methods in models, preliminary human trials have been mainly unsatisfactory. Mybpc-3 delivery by adeno-associated virus (AAV) expressing cardiac myosin-binding protein C reduced the development of HCM in a mouse model. HCM-mutant mRNA expressing myosin-binding protein C was also corrected by 5′trans-splicing, which prevented the development of HCM in newborn animals with frame-shift mutations. Gedicke-Hornung et al created a modified mRNA and protein expressed by the Mybpc-3 gene that decreased a fatal mutation in a newborn mouse and avoided the development of HCM. 247 An AAV-delivered RNAi strategy that exclusively targets the mutant Mhy6 allele that encodes myosin heavy chain has also been found to postpone the development of cardiac hypertrophy and fibrosis. (100,101,102)

Diltiazem, a calcium channel blocker, has been proven in a mouse model in a small randomized human pilot experiment in MYBP-3 carriers to prevent the development of HCM. The VANISH study [NCT01912534] assigned 150 sarcomere mutation carriers with no or mild symptoms to the angiotensin receptor blocker valsartan or placebo. The outcomes are anticipated in 2019.(103,104)

MYK-461 is an orally given small drug that allosterically inhibits myosin ATPase activity, reduces myocyte force generation, and has been found to decrease the development of cardiac hypertrophy, myocyte disarray, and fibrosis in a mouse model of HCM 250. This drug is presently being investigated in a Phase 2 trial in patients with HCM with LVOT blockage, following the successful completion of three Phase I clinical studies. [NCT02842242] (105)

Since its contemporary classification quite a half-century ago, improvement within the diagnosis and care of people with HCM has mirrored technical breakthroughs in genetic testing, cardiac imaging, arrhythmia prevention, cardiac surgery, and interventional cardiology. Improved annotation of human genetic variations and their varied relationship to clinical expression is anticipated to help in identifying those who have harmful variants. it'll provide much-needed information on the prognosis of the growing number of such persons, many of whom are relatives of patients with HCM and who harbor the identical mutation but don't have any observable manifestations of HCM. (106,107,108)

In the future, such people may be subjected to therapies aimed at slowing or preventing conversion to phenotypic positive. These may include pharmaceutical therapies as well as other interventions that are currently in the experimental stage.

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

Furthermore, much more has to be known about non-mutation carriers who are phenotypic positive, including sporadic instances of HCM, to discover any "missing" causative genes and their natural history.

One in every 500 Americans is affected with hypertrophic cardiomyopathy, which affects an estimated 600,000 to 1.5 million people. It is more common than multiple sclerosis, which affects one out of every 700 individuals.

HCM affects one out of every 500 persons, although a substantial number of sufferers go undiagnosed. Two-thirds of individuals diagnosed have obstructive HCM, whereas one-third have non-obstructive HCM.

Statistical analysis :

The current study was conducted in a global population of 744 consecutively recruited and mostly unselected individuals who were more representative of the whole HCM spectrum. Over 87 years (mean SD), 86 individuals (12%) died as a result of HCM. There were three separate ways of death: [(109)] abrupt and unexpected (51%; age, 4520 years); [(110)] progressive heart failure (36%; age, 5619 years); and (3) HCM-related stroke linked with atrial fibrillation (13%; age, 7314 years).

Sudden death was more prevalent in young patients, but heart disease and stroke-related fatalities were more common in those in their forties and fifties. However, neither extra time nor heart failure-related mortality had a statistically significant, disproportionate age distribution (P=0.06 and 0.5, respectively). Stroke-related fatalities were more common in elderly individuals (P=0.002). the bulk (71%) of the 45 patients who died unexpectedly had no or mild symptoms, while 7 (16%) were engaged in moderate to severe physical activity at the time of death. [(111)]



The worldwide hypertrophic cardiomyopathy (HCM) therapies market is expected to expand at a CAGR of about 1.5 percent during the projected period. The high prevalence of CVD is a primary factor driving market expansion. As per the World Health Organization (WHO), CVDs are the major cause of mortality across the globe. CVD caused about 17.9 million deaths in 2016, accounting for 31% of all worldwide deaths. Stroke and heart attack were responsible for 85 percent of these deaths. HCM is a hereditary cardiac condition characterized by an increase in the wall thickness of the left ventricle. It is generally caused by faulty genes in the heart muscle, which induce left ventricle writhing.[(112)]

Based on the literature it is identified that, clinically HCM patients living in 122 countries (64 percent of the 191 countries with populations greater than 500,000) according to cardiologists in many countries, and interrogation of clinical records from the Tufts HCM Institute and the patient advocacy organization (Hypertrophic Cardiomyopathy Association). Notably, the populations of nations known to have HCM patients amount to 6.3 billion people, or 88 percent of the world population (i.e., 7.13 billion), including India and China, which each have 2.7 billion people.

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

There is recent evidence of increased emphasis and focus on HCM in India, China, and elsewhere, with the establishment of multidisciplinary HCM centers dedicated to the diagnosis and therapy of this illness. In southern India, for example, the first HCM center in the country was established at the Amrita Institute of Medical Sciences and Research in Kochi, Kerala, under the direction of Dr. Hisham Ahamed, now with a cohort of 700 patients assembled in only three years, many of whom required specialized care. Fuwai Hospital in Beijing has become a national referral center for HCM, with a high-volume, well-executed surgical myectomy program (Dr. Shuiyun Wang). [113]

Screening for the condition has been urged, several studies have important findings HCM is the most prevalent hereditary cardiovascular illness and the greatest cause of sudden cardiac death among young athletes in the United States and one study found the incidence of death of David Frost in united kingdom.

United States:

There are many possible problems connected with regular HCM screening in the United States. [114] For starters, the projected athlete population in the United States is 15 million, which is about double that of Italy. Second, these occurrences are uncommon, with less than 100 deaths in the United States owing to HCM among elite athletes each year[115] or roughly one fatality every 220,000 athletes. [116] Finally, genetic testing would offer a definite diagnosis; but, because of the many HCM-causing mutations, this form of screening is complicated and not cost-effective. [117] As a result, genetic testing in the United States is confined to individuals with obvious symptoms of HCM and their family members.

United Kingdom :

Following the death of TV personality David Frost in 2013, a post-mortem examination revealed that he had HCM, however, it did not lead to his death, and his family was not told. His 31-year-old son's unexpected cardiac death in 2015 prompted the family to work with the British Heart Foundation to collect funding for improved screening. [118]

Canada :

The following are Canadian genetic testing guidelines and recommendations for people with HCM: [119]

1. The primary goal of genetic testing is to screen family members.
2. According to the findings, families who are at risk may be urged to undergo thorough testing.
3. Genetic testing is not intended to confirm a diagnosis.
4. If the diagnosed person has no relatives who are at risk, genetic testing is not necessary.
5. Genetic testing is not meant to be used to assess risk or make treatment decisions.
6. Only clinical testing predicts the course and risk of developing complications of HCM, according to the evidence.
7. Individuals suspected of having HCM should:
8. Genetic testing is now available. [120]

Conclusions:

For long years, HCM was regarded as an uncommon and unique disease, with few effective management techniques and no therapeutic choices for SD risk. Over the last two decades, advancements in the detection and therapy of cardiovascular disease (mostly atherosclerotic CAD) have transferred into hereditary heart disorders such as HCM. Many investigators from across the world have worked together to better characterize the clinical and morphological spectrum and natural history of HCM, capturing its extraordinary variability, complexity, and unpredictability. [121,122]

Although the cardiology community should be more optimistic about HCM than in past times, it remains a complicated disease entity that requires sustained concentrated research to face several future difficulties. Although the ICD is a validated tool for preserving life in HCM, there is still a pressing need to more accurately determine which patients would benefit from this therapy. Pharmacological therapy to manage HF symptoms has remained stable for many years, necessitating innovation to find new medicines targeted to HCM. Even though the molecular era has enabled quick genetic testing to identify family members at risk of development, Although the molecular era has enabled quick genetic testing to identify family members at

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

risk of developing HCM, the genetic basis for a significant number of individuals remains unclear. Finally, there is a need to better understand the structural and metabolic derangements produced by pathogenic mutations to create new treatments that target critical disease progression pathways.[123]

Reference:

(1)Basit, Hajira; Brito, Daniel; Sharma, Saurabh (2020), "Hypertrophic Cardiomyopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 28613539, retrieved 2020-09-2.

(2) Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular genetics of familial hypertrophic cardiomyopathy (FHC). J Hum Genet. 2003;48(2):55-64. Review. Citation on PubMed

(3) Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Clin Pract Cardiovasc Med. 2008 Mar;5(3):158-68. doi: 10.1038/ncpcardio1110. Epub 2008 Jan 29. Review. Erratum in: Nat Clin Pract Cardiovasc Med. 2008 Nov;5(11):747. Citation on PubMed

(4) Kimura A. Molecular genetics and pathogenesis of cardiomyopathy. J Hum Genet. 2016 Jan;61(1):41-50. doi: 10.1038/jhg.2015.83. Epub 2015 Jul 16. Review. Citation on PubMed

(5) By Matthew Hoffman, MD Medically Reviewed by Carol DerSarkissian, MD on June 23, 2021 https://www.webmd.com/heart/picture-of-the-heart

(6) Medical Author: Shaziya Allarakha, MD,Medical Editor: Pallavi Suyog Uttekar, MD , Medically Review ed on 9/14/2021 "what are the four main functions" https://www.medicinenet.com/what_are_the_four_main_functions_of_the_heart/article.htm

(7) Moore, Keith L.; Dalley, Arthur F.; Agur, Anne M. R. (2009). "1". Clinically Oriented Anatomy. Wolters Kluwel Health/Lippincott Williams & Wilkins. pp. 127–173. ISBN 978-1-60547-652-0.

(8) Greenbaum R, Ho SY, Gibson DG, Becker AE, Anderson RH. Left ventricular fibre architecture in man, Br Heart J, 1981, vol. 54 (pg. 248-63)

(9) Sanchez-Quintana D, Climent V, Ho SY, Anderson RH. Myoarchitecture and connective tissue in hearts with tricuspid atresia, Heart, 1999, vol. 81 (pg. 182-91)

(10) Sanchez-Quintana D, Garcia-Martinez V, Climent V, Hurle JM. Morphological changes in the normal pattern of ventricular myoarchitecture in the developing human heart, Anat Rec, 1995, vol. 243 (pg. 483-95)

(11) Harrisons principles of Internal medicine, 20E (2018)

(12) ESC working group on myocardial pericardial diseases (Elliott P et al. EHJ 2007)

(13) Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT and Bild DE: Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 92:785–789. 1995. View Article : Google Scholar : PubMed/NCBI

(14) Maron BJ and Maron MS: Hypertrophic cardiomyopathy. Lancet. 381:242–255. 2013. View Article : Google Scholar : PubMed/NCBI

(15) Semsarian C, Ingles J, Maron MS and Maron BJ: New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 65:1249–1254. 2015. View Article : Google Scholar : PubMed/NCBI

(16) Maron BJ: Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy. Circulation. 121:445–456. 2010. View Article : Google Scholar : PubMed/NCBI

ISSN:0975-3583.0976-2833 VOL12.ISSUE05.2021

(17) Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, et al: Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: A scientific statement from the American heart association council on nutrition, physical activity, and metabolism: Endorsed by the American college of cardiology foundation. Circulation. 115:1643–1655. 2007. View Article : Google Scholar : PubMed/NCBI

(18) Ahmad F, Seidman JG and Seidman CE: The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet. 6:185–216. 2005. View Article : Google Scholar : PubMed/NCBI

(19) Waldmüller S, Sakthivel S, Saadi AV, Selignow C, Rakesh PG, Golubenko M, Joseph PK, Padmakumar R, Richard P, Schwartz K, et al: Novel deletions in MYH7 and MYBPC3 identified in Indian families with familial hypertrophic cardiomyopathy. J Mol Cell Cardiol. 35:623–636. 2003. View Article : Google Scholar : PubMed/NCBI

(20) Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, et al: 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 124:2761–2796. 2011. View Article : Google Scholar : PubMed/NCBI

(21) Authors/Task Force members, ; Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, et al: 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European society of cardiology (ESC). Eur Heart J. 35:2733–2779. 2014. View Article : Google Scholar : PubMed/NCBI

(22)- NHLBI. 22 June 2016. Archived from the original on 4 October 2017. Retrieved 10 November 201

(23)- Basit, Hajira; Brito, Daniel; Sharma, Saurabh (2020), "Hypertrophic Cardiomyopathy", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 28613539, retrieved 2020-09-20

(24) Teare D (January 1958). "Asymmetrical hypertrophy of the heart in young adults". British Heart Journal. **20** (1)

(25)- Fifer MA, Vlahakes GJ (January 2008). "Management of symptoms in hypertrophic cardiomyopathy". Circulation. **117** (3): 429–39. doi:10.1161/CIRCULATIONAHA.107.694158. PMID 18212300

(26)- Bonow R, Braunwald E, Zipes DP, Libby P (2005). "The Cardiomyopathies". Braunwald's heart disease: a textbook of cardiovascular medicine (7th ed.). Philadelphia: WB Saunders. ISBN 978-1-4160-0014-3

(27)- Kalyva A, Parthenakis FI, Marketou ME, Kontaraki JE, Vardas PE (April 2014). "Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies". Journal of Muscle Research and Cell Motility. **35** (2): 161–78. doi:10.1007/s10974-014-9382-0. PMID 24744096. S2CID 1726747.

(28)- Murphy JG, Lloyd MA (2007). Mayo Clinic Cardiology Concise Textbook and Mayo Clinic Cardiology Board Review Questions & Answers: (TEXT AND Q&A SET). CRC Press. p. 1159. ISBN 9781439825457. Archived from the original on 2018-10-23. Retrieved 2018-10-22.

(29) - Cirino AL, Ho C (2014). "Hypertrophic Cardiomyopathy Overview". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.). GeneReviews. University of Washington, Seattle. PMID 20301725.

(30)- Pasquale F, Syrris P, Kaski JP, Mogensen J, McKenna WJ, Elliott P (February 2012). "Long-term outcomes in hypertrophic cardiomyopathy caused by mutations in the cardiac troponin T gene". Circulation: Cardiovascular Genetics. **5** (1): 10–7. doi:10.1161/CIRCGENETICS.111.959973. PMID 22144547
(31)- Barry J. Maron, Ethan J. Rowin, and Martin S. Maron J Am Coll Cardiol HF. 2018 May, 6 (5) 376–378
(32)- Vulpian A. Contribution à l'étude des rétrécissements de l'orifice ventriculo-aortique. Arch. Physiol. 1868;3:456–457. [Google Scholar]

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

(33)- Liouville H. Rétrécissement cardiaque sous aortique. Gaz. Med. Paris. 1869;24:3. [Google Scholar]
(34). Hallopeau M. Rétrécissement ventriculo-aortique. Gaz. Med. Paris. 1869;24:4. [Google Scholar]

(35) Teare D. Asymmetrical hypertrophy of the heart in young adults. Br. Heart J. 1958;20:1–8. doi: 10.1136/hrt.20.1.1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
(36) Brock R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis. Guys Hosp. Rep. 1957;106:221–238. [PubMed] [Google Scholar]
(37) Bercu B.A., Diettert G.A., Danforth W.H., Pund E.E., Ahlvin R.C., Belliveau R.R. Pseudoaortic stenosis produced by ventricular hypertrophy. Am. J. Med. 1958;25:814–818. doi: 10.1016/0002-9343(58)90021-4. [PubMed] [CrossRef] [Google Scholar]
(38) W.L. Henry, C.E. Clark, S.E. Epstein, Asymmetric septal hypertrophy: Echocardiographic identification of the pathognomic anatomic abnormality of IHSS, Circulation, 47 (1973), pp. 225-233
(39) J.A. Jarcho, W.J. McKenna, J.A. Pare, et al. Mapping a gene for familial hypertrophic cardiomyopathy to chromosome 14q1, N Engl J Med, 321 (1989), pp. 1372-137
(40) A.A. Geisterfer-Lowrance, S. Kass, G. Tanigawa, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation, Cell, 62 (1990), pp. 999-1006

(41)- Bos J.M., Towbin J.A., Ackerman M.J. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2009;54:201–211. doi: 10.1016/j.jacc.2009.02.07

(42)- Veselka J., Anavekar N.S., Charron P. Hypertrophic obstructive cardiomyopathy. Lancet. 2017;389:1253–1267. doi: 10.1016/S0140-6736(16)31321-6. [PubMed] [CrossRef] [Google Scholar]

(43)- Correia E., Rodrigues B., Santos L.F., Moreira D., Gama P., Cabral C., Santos O. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: Correlation with nonsustained ventricular tachycardia. Echocardiography. 2011;28:709–714.

(44)- Panza JA, Naidu SS. Historical Perspectives in the Evolution of Hypertrophic Cardiomyopathy. Cardiol Clin. 2019 Feb;37(1):1-10. doi: 10.1016/j.ccl.2018.08.001. PMID: 30447709.

(45)- Torpy JM, Glass TJ, Glass RM. Left Ventricular Hypertrophy. JAMA. 2004;292(19):2430. doi:10.1001/jama.292.19.2430

(46)- Sakellaropoulos S, Svab S, Mohammed M, Dimitra L, Mitsis A. The Role of Mitral Valve in Hypertrophic Obstructive Cardiomyopathy: An Updated Review. Curr Probl Cardiol. 2021 Mar;46(3):100641. doi: 10.1016/j.cpcardiol.2020.100641. Epub 2020 Jun 4. PMID: 32586596.

(47)- Tejado BSM, Jou C. Histopathology in HCM. Glob Cardiol Sci Pract. 2018 Aug 12;2018(3):20. doi: 10.21542/gcsp.2018.20. PMID: 30393632; PMCID: PMC6209442.

(48)- Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017;121(7):749-770. doi:10.1161/CIRCRESAHA.117.311059

(49)- Ramaraj R. Hypertrophic cardiomyopathy: etiology, diagnosis, and treatment. Cardiol Rev. 2008 Jul-Aug;16(4):172-80. doi: 10.1097/CRD.0b013e318178e525. PMID: 18562807.

(50) -Maron BJ, Rowin EJ, Maron MS. Global Burden of Hypertrophic Cardiomyopathy. JACC Heart Fail. 2018 May;6(5):376-378. doi: 10.1016/j.jchf.2018.03.004. PMID: 29724362.
(51) D.J. Tester, M.J. Ackerman, Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice, Circulation, 123 (2011), pp. 1021-1037
(52) A.P. Landstrom, M.J. Ackerman, Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy, Circulation, 122 (2010), pp. 2441-2449
(53) C.S. Richards, S. Bale, D.B. Bellissimo, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007, Genet Med, 10 (2008), pp. 294-300

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

(54) L. Mestroni, M.R. Taylor Hearing the noise, the challenges of human genome variation in genetic testing, J Am Coll Cardiol, 57 (2011), pp. 2328-2329
(55) B. Meder, J. Haas, A. Keller, et al.Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies, Circ Cardiovasc Genet, 4 (2011), pp. 110-122
(56) The 1000 Genomes Project Consortium, A map of human genome variation from populations—scale sequencing. Nature, 467 (2010), pp. 1061-1073
(57)- Lind JM, Chiu C, Semsarian C. Genetic basis of hypertrophic cardiomyopathy. Expert Rev Cardiovasc Ther. 2006 Nov;4(6):927-34. doi: 10.1586/14779072.4.6.927. PMID: 17173506.
(58)- Marian AJ. Molecular Genetic Basis of Hypertrophic Cardiomyopathy. Circ Res. 2021 May 14;128(10):1533-1553. doi: 10.1161/CIRCRESAHA.121.318346. Epub 2021 May 13. PMID: 33983830; PMCID: PMC8127615.
(59)-Teekakirikul, P., Zhu, W., Huang, H. C., & Fung, E. (2019). Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules, 9(12), 878. https://doi.org/10.3390/biom9120878
(60)-Rivera-Diaz J, Moosvi AR (July 1996). "Apical hypertrophic cardiomyopathy". Southern Medical Journal. **89** (7): 711–3. doi:10.1097/00007611-199607000-00012. PMID 8685759
(61)-Krasnow N. Subaortic septal bulge simulates hypertrophic cardiomyopathy by angulation of the septum with age, independent of focal hypertrophy. An echocardiographic study. J Am Soc Echocardiogr. 1997 Jun;10(5):545-55. doi: 10.1016/s0894-7317(97)70009-9. PMID: 9203495.
(62)- Bishu K, Coylewright M, Nishimura R. The role of hemodynamic catheterization in the evaluation of hypertrophic obstructive cardiomyopathy: A case series. Catheter Cardiovasc Interv. 2015 Nov;86(5):903-12. doi: 10.1002/ccd.25856. Epub 2015 Feb 18. PMID: 25620326.
(63)-Brock R. Functional obstruction of the left ventricle; acquired aortic subvalvar stenosis.**Guys Hosp Rep**. 1957; 106:221–238.
(64)- BROCK R. Functional obstruction of the left ventricle (acquired aortic subvalvar stenosis).**Guys Hosp Rep**. 1959; 108:126–143.
(65)- Morrow AG, Braunwald E. Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction.**Circulation**. 1959; 20:181–189
(66)- Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, Nistri S, Cecchi F, Udelson JE, Maron BJ. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.**Circulation**. 2006; 114:2232–2239. doi: 10.1161/CIRCULATIONAHA.106.644682.
(67)- Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, Ward D, Kohli SK, Page SP, Demetrescu C, Sevdalis E, Keren A, Pellerin D, McKenna WJ, Elliott PM. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy.**Heart**. 2008; 94:1288–1294. doi: 10.1136/hrt.2007.126003.
(68)- Braunwald E, Oldham HN, Ross J, Linhart JW, Mason DT, Fort LThe circulatory response of patients with idiopathic hypertrophic subaortic stenosis to nitroglycerin and to the valsalva maneuver.**Circulation**. 1964; 29:422–431
(69)- Braunwald E, Ebert PA. Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs.**Am J Cardiol**. 1962; 10:489–495.
(70)- Stewart S, Mason DT, Braunwald E. Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis.**Circulation**. 1968; 37:8–14
(71)- Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia-Pavia P, McKenna WJ, Omar RZ, Elliott PM; Hypertrophic Cardiomyopathy Outcomes Investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).**Eur J Heart Fail**. 2015; 17:837–845. doi: 10.1002/ejhf.316.
(72)- Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW, Quiñones MA, Roberts R, Marian AJ. Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease.**Circulation**. 2003; 108:395–398. doi: 10.1161/01.CIR.0000084500.72232.8D.
(73)- Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L. Regional heterogeneity of function in hypertrophic cardiomyopathy.**Circulation**. 1994; 90:186–194
(74)- Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy.**Circ Cardiovasc Imaging**. 2014; 7:11–19. doi: 10.1161/CIRCIMAGING.113.000842.
(75) Maron BJ (March 2002). "Hypertrophic cardiomyopathy: a systematic review". JAMA. 287 (10): 1308–20. doi:10.1001/jama.287.10.1308. PMID 11886323
(76)- Fifer MA, Vlahakes GJ (January 2008). "Management of symptoms in hypertrophic cardiomyopathy". Circulation. **117** (3): 429–39. doi:10.1161/CIRCULATIONAHA.107.694158. PMID 18212300

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

(77)-Wigle ED, Rakowski H, Kimball BP, Williams WG (October 1995). "Hypertrophic cardiomyopathy. Clinical spectrum and treatment". Circulation. **92** (7): 1680–92. doi:10.1161/01.cir.92.7.1680. PMID 7671349.

(78) Jump up to:[a] [b] [c] Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. (November 2003). "American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines". Journal of the American College of Cardiology. **42** (9): 1687–713. doi:10.1016/S0735-1097(03)00941-0. PMID 14607462.

(79)- Kalyva A, Parthenakis FI, Marketou ME, Kontaraki JE, Vardas PE (April 2014). "Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies". Journal of Muscle Research and Cell Motility. **35** (2): 161–78. doi:10.1007/s10974-014-9382-0. PMID 24744096. S2CID 1726747.

(80)- Murphy JG, Lloyd MA (2007). Mayo Clinic Cardiology Concise Textbook and Mayo Clinic Cardiology Board Review Questions & Answers: (TEXT AND Q&A SET). CRC Press. p. 1159. ISBN 9781439825457. Archived from the original on 2018-10-23. Retrieved 2018-10-22.

(81) Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. (November 2003). "American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines". Journal of the American College of Cardiology. **42** (9): 1687–713. doi:10.1016/S0735-1097(03)00941-0. PMID 14607462.

(82) Kalyva A, Parthenakis FI, Marketou ME, Kontaraki JE, Vardas PE (April 2014). "Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies". Journal of Muscle Research and Cell Motility. **35** (2): 161–78. doi:10.1007/s10974-014-9382-0. PMID 24744096. S2CID 1726747.

(83) Murphy JG, Lloyd MA (2007). Mayo Clinic Cardiology Concise Textbook and Mayo Clinic Cardiology Board Review Questions & Answers: (TEXT AND Q&A SET). CRC Press. p. 1159. ISBN 9781439825457. Archived from the original on 2018-10-23. Retrieved 2018-10-22.

(84)-Wigle EDThe diagnosis of hypertrophic cardiomyopathyHeart 2001;**86:**709-714.

(85)-diagnosis | Hypertrophic Cardiomyopathy (cardiomiopatiaipertrofica.info)

(86)-Sievert H, Qureshi SA, Wilson N, Hijazi ZM (2015). Interventions in Structural, Valvular and Congenital Heart Disease (second ed.). CRC Press. p. 46. ISBN 9781482215649. Archived from the original on 2018-01-03. Retrieved 2018-01-02.

(87)- Rivera-Diaz J, Moosvi AR (July 1996). "Apical hypertrophic cardiomyopathy". Southern Medical Journal. **89** (7): 711–3. doi:10.1097/00007611-199607000-00012

(88)- Critoph C, Elliott P (December 2010). "Hypertrophic Cardiomyopathy". Cardiac Electrophysiology Clinics. **2** (4): 587–598. doi:10.1016/j.ccep.2010.09.010. PMID 28770721

(89)-Zampieri, M., Berteotti, M., Ferrantini, C. et al. Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives . Curr Heart Fail Rep **18,** 169–179 (2021). https://doi.org/10.1007/s11897-021-00523-0

(90)- Sherrid MV, Chaudhry FA, Swistel DG (February 2003). "Obstructive hypertrophic cardiomyopathy: echocardiography, pathophysiology, and the continuing evolution of surgery for obstruction". The Annals of Thoracic Surgery. **75** (2): 620–32. doi:10.1016/S0003-4975(02)04546-0. PMID 12607696.

(91)- Messmer BJ (August 1994). "Extended myectomy for hypertrophic obstructive cardiomyopathy". The Annals of Thoracic Surgery. **58**(2): 575–7. doi:10.1016/0003-4975(94)92268-3. PMID 8067875.

ISSN:0975-3583.0976-2833 VOL12.ISSUE05.2021

(92)- Schoendube FA, Klues HG, Reith S, Flachskampf FA, Hanrath P, Messmer BJ (November 1995). "Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus". Circulation. **92** (9 Suppl): II122-7. doi:10.1161/01.CIR.92.9.122. PMID 7586394.

(93)-Jump up to:**[a] [b]** Balaram SK, Sherrid MV, Derose JJ, Hillel Z, Winson G, Swistel DG (July 2005). "Beyond extended myectomy for hypertrophic cardiomyopathy: the resection-plication-release (RPR) repair". The Annals of Thoracic Surgery. **80** (1): 217–23. doi:10.1016/j.athoracsur.2005.01.064. PMID 15975370

(94)-Dimitrow PP, Rajtar-Salwa R (May 2016). "Obstructive Form of Hypertrophic Cardiomyopathy-Left Ventricular Outflow Tract Gradient: Novel Methods of Provocation, Monitoring of Biomarkers, and Recent Advances in the Treatment". BioMed Research International. **2016**: 1575130. doi:10.1155/2016/1575130. PMC 4877458. PMID 2724793

(95)-Sorajja P, Pedersen WA, Bae R, Lesser JR, Jay D, Lin D, et al. (June 2016). "First Experience with Percutaneous Mitral Valve Plication as Primary Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy". Journal of the American College of Cardiology. **67** (24): 2811–8. doi:10.1016/j.jacc.2016.03.587. PMID 27311518.

(96) Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ (July 1999). "Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points". Journal of the American College of Cardiology. **34** (1): 191–6. doi:10.1016/S0735-1097(99)00173-4. PMID 10400010

(97)-Marian, A. J., & Braunwald, E. (2017). Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation research, 121(7), 749–770. https://doi.org/10.1161/CIRCRESAHA.117.311059

(98)-Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW, Quinones MA, Roberts R, Marian AJ. Tissue doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation. 2003;108:395–398. [PMC free article] [PubMed] [Google Scholar]

(99)-Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE, Desnick RJ, Germain DP, International Fabry Disease Study Group. Am J Hum Genet. 2004 Jul; 75(1):65-74.[PubMed] [Ref list]

(100)-The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.
Ho CY, Day SM, Colan SD, Russell MW, Towbin JA, Sherrid MV, Canter CE, Jefferies JL, Murphy AM, Cirino AL, Abraham TP, Taylor M, Mestroni L, Bluemke DA, Jarolim P, Shi L, Sleeper LA, Seidman CE, Orav EJ, HCMNet Investigators.
JAMA Cardiol. 2017 Apr 1; 2(4):419-428.

(101)-Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy.
Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, Quiñones MA, Roberts R, Marian AJ
Circulation. 2001 Jul 10; 104(2):128-30.

(102)-Toronto hypertrophic cardiomyopathy genotype score for prediction of a positive genotype in hypertrophic cardiomyopathy.
Gruner C, Ivanov J, Care M, Williams L, Moravsky G, Yang H, Laczay B, Siminovitch K, Woo A, Rakowski H
Circ Cardiovasc Genet. 2013 Feb; 6(1):19-26.

(103)-A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice.
Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudich JA, McDowell RS, Seidman JG, Seidman CE
Science. 2016 Feb 5; 351(6273):617-21.

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

(104)-The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial.
Ho CY, McMurray JJV, Cirino AL, Colan SD, Day SM, Desai AS, Lipshultz SE, MacRae CA, Shi L, Solomon SD, Orav EJ, Braunwald E, VANISH trial investigators and executive committee.
Am Heart J. 2017 May; 187():145-155.

(105)-Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
Ho CY, Lakdawala NK, Cirino AL, Lipshultz SE, Sparks E, Abbasi SA, Kwong RY, Antman EM, Semsarian C, González A, López B, Diez J, Orav EJ, Colan SD, Seidman CE
JACC Heart Fail. 2015 Feb; 3(2):180-8.

(106)-Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy.Jiang J, Wakimoto H, Seidman JG, Seidman CEScience. 2013 Oct 4; 342(6154):111-4
(107)-Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice.
Gedicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, Schlossarek S, Précigout G, Braren I, Eschenhagen T, Mearini G, Lorain S, Voit T, Dreyfus PA, Garcia L, Carrier L
EMBO Mol Med. 2013 Jul; 5(7):1128-45

(108)-Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, Quinones MA, Zoghbi WA, Entman ML, Roberts R, Marian AJ
Circulation. 2001 Jul 17; 104(3):317-24.

(109)-Maron B.J., Rowin E.J., Casey S.A. and Maron M.S. : "How hypertrophic cardiomyopathy became a contemporary treatable genetic disease with low mortality: shaped by 50 years of clinical research and practice". JAMA Cardiol 2016; **1**: 98.

(110)- Kubo T., Hirota T., Baba Y.et al. : "Patients' characteristics and clinical course of hypertrophic cardiomyopathy in a regional Japanese cohort: results from Kochi RYOMA study". Circ J 2018; **82**: 824.

(111) -Semsarian C., Ingles J., Maron M.S. and Maron B.J. : "New perspectives on the prevalence of hypertrophic cardiomyopathy". J Am Coll Cardiol 2015; **65**: 1249.

(112)-Maron B.J. : "Importance and feasibility of creating hypertrophic cardiomyopathy centers in developing countries: the experience in India". Am J Cardiol 2015; **116**: 332.

(113)-Tang B., Song Y., Cui H.et al. : "Prediction of mid-term outcomes in adult obstructive hypertrophic cardiomyopathy after surgical ventricular septum myectomy". J Am Coll Cardiol 2017; **70**: 2092

(114)-Maron BJ (March 2010). "National electrocardiography screening for competitive athletes: Feasible in the United States?". Annals of Internal Medicine. **152** (5): 324–6.

(115) -Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO (March 2009). "Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006". Circulation. **119** (8): 1085–92.

(116)Maron BJ, Gohman TE, Aeppli D (December 1998). "Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes". Journal of the American College of Cardiology. **32** (7): 1881–4.

(117)-Maron BJ (March 2002). "Hypertrophic cardiomyopathy: a systematic review". JAMA. **287** (10): 1308–20

(118)- Hershberger RE, Lindenfeld J, Mestroni L, Seidman CE, Taylor MR, Towbin JA (March 2009). "Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline". Journal of Cardiac Failure. **15** (2): 83–97.

ISSN:0975-3583,0976-2833 VOL12,ISSUE05,2021

(119)- Espinoza J (31 January 2016). "Sir David Frost's son 'unaware of fatal heart condition'". Daily Telegraph. Archived from the original on 20 January 2019. Retrieved 1 February 2016

(120)- Gollob MH, Blier L, Brugada R, Champagne J, Chauhan V, Connors S, et al. (2011). "Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper". The Canadian Journal of Cardiology. **27** (2): 232–45

(121)- Hypertrophic Cardiomyopathy in the General Population: Leveraging the UK Biobank Database and Machine Learning Phenotyping Baudhuin L.M. **Journal of the American College of Cardiology** • 14 September 2021 • Pages 1111-1113

(122)- Successful therapeutic hypothermia in patients with hypertrophic cardiomyopathy B.J. Maron, … +2 … , et al. J Am Coll Cardiol, 57 (2011), pp. 2454-2456

(123) - Recognition of hypertrophic cardiomyopathy as a contemporary, relatively common and treatable disease: International Summit V B.J. Maron Am J Cardiol, 113 (2014), pp. 739-744